Tumor Biology

, Volume 36, Issue 6, pp 4339–4348 | Cite as

Nicotinamide induces apoptosis of F9 mouse teratocarcinoma stem cells by downregulation of SATB1 expression

  • Yan Zhang
  • Haibo Wu
  • Man Zhang
  • Yali Jiang
  • Weiwei Zhuo
  • Yong Zhang
  • Song Hua
Research Article


The aim of this study was to decide whether nicotinamide (NA) could induce apoptosis of F9 mouse teratocarcinoma stem cells (MF9) by downregulation of special AT-rich sequence binding protein 1 (SATB1) expression. We used different concentrations of NA (0, 1.5, 2, and 2.5 mmol/L) to treat MF9 cells and analyze SATB1 expression by RT-qPCR and Western blotting; in addition, the cell proliferation was detected in a microplate reader with Cell Counting Kit-8 (CCK-8), and the cell cycle and apoptosis were analyzed using flow cytometry. We found that the expression of SATB1 was decreased significantly in NA-treated groups than in the control group, and its expression level was inversely related to the NA concentration. In addition, CCK-8 analysis showed that NA significantly inhibited the proliferation of MF9 cells, and flow cytometry showed that NA blocked MF9 cells to G1 phase and significantly promoted apoptosis in any treated groups. To confirm the results, we constructed small interference RNA (siRNA) targeting at mouse SATB1 and transferred into MF9 cells. The results indicated that the expression of SATB1 in both mRNA and protein levels was significantly decreased after cells transferred with siRNA sequence for 48 h, the proliferation of MF9 cells was significantly inhibited, and most of MF9 cells were blocked at G1 phase, and the apoptosis rate was increased obviously. The results showed that NA could inhibit the proliferation and induce apoptosis of MF9 cells. These findings might be used as an efficient candidate for teratocarcinoma therapy.


Nicotinamide Teratocarcinoma SATB1 siRNA Apoptosis 



The work was supported by National Natural Science Foundation of the People’s Republic of China (No. 31001008).

Conflicts of interest



  1. 1.
    Sonee M, Martens JR, Mukherjee SK. Nicotinamide protects HCN2 cells from the free radical generating toxin, tertiary-butylhydroperoxide (t-BuOOH). Neurotox Res. 2002;4:595–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Jin J, Lee KB, Park SY, Jang JJ. Nicotinamide inhibits hepatic fibrosis by suppressing DNA synthesis and enhancing apoptosis of hepatic stellate cells. Virchows Arch. 2011;458:689–96.CrossRefPubMedGoogle Scholar
  3. 3.
    Saldeen J, Tillmar L, Karlsson E, Welsh N. Nicotinamide-and caspase-mediated inhibition of poly(ADP-ribose) polymerase are associated with p53-independent cell cycle (G2) arrest and apoptosis. Mol Cell Biochem. 2003;243:113–22.CrossRefPubMedGoogle Scholar
  4. 4.
    Audrito V, Vaisitti T, Rossi D, Gottardi D, D’Arena G, Laurenti L, et al. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res. 2011;71:4473–83.CrossRefPubMedGoogle Scholar
  5. 5.
    Fernandes CA, Fievez L, Ucakar B, Neyrinck AM, Fillee C, Huaux F, et al. Nicotinamide enhances apoptosis of G(M)-CSF-treated neutrophils and attenuates endotoxin-induced airway inflammation in mice. Am J Physiol Lung Cell Mol Physiol. 2011;300:L354–61.CrossRefPubMedGoogle Scholar
  6. 6.
    Luo JY, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001;107:137–48.CrossRefPubMedGoogle Scholar
  7. 7.
    Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303:2011–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell. 2004;116:551–63.CrossRefPubMedGoogle Scholar
  9. 9.
    Hoane MR, Kaplan SA, Ellis AL. The effects of nicotinamide on apoptosis and blood-brain barrier breakdown following traumatic brain injury. Brain Res. 2006;1125:185–93.CrossRefPubMedGoogle Scholar
  10. 10.
    Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T. A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell. 1992;70:631–45.CrossRefPubMedGoogle Scholar
  11. 11.
    Shen ZH, Zeng YM, Guo JL, Wu YX, Jiang XF, Ding R, et al. Over-expression of the special AT rich sequence binding protein 1 (SATB1) promotes the progression of nasopharyngeal carcinoma: association with EBV LMP-1 expression. J Transl Med. 2013. doi: 10.1186/1479-5876-11-217.Google Scholar
  12. 12.
    Chu SH, Ma YB, Feng DF, Zhang H, Qiu JH, Zhu ZA, et al. Relationship between SATB1 expression and prognosis in astrocytoma. J Clin Neurosci. 2013;20:543–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, Wang R, et al. Correlation of SATB1 overexpression with the progression of human rectal cancer. Int J Colorectal Dis. 2012;27:143–50.CrossRefPubMedGoogle Scholar
  14. 14.
    Endo K, Shackelford J, Aga M, Yoshizaki T, Pagano JS. Upregulation of special AT-rich-binding protein 1 by Epstein–Barr virus latent membrane protein 1 in human nasopharyngeal cells and nasopharyngeal cancer. J Gen Virol. 2013;94:507–13.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M. The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst. 2010;102:1284–96.CrossRefPubMedGoogle Scholar
  16. 16.
    Patani N, Jiang W, Mansel R, Newbold R, Mokbel K. The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int. 2009. doi: 10.1186/1475-2867-9-18.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Fang FX, Hou ZB, Dai XZ, Chen C, Ge J, Shen H, et al. Special AT-rich sequence-binding protein 1 promotes cell growth and metastasis in colorectal cancer. World J Gastroenterol. 2013;19:2331–9.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008;452:187–93.CrossRefPubMedGoogle Scholar
  19. 19.
    Mao LJ, Yang CH, Wang JQ, Li W, Wen RM, Chen JC, et al. SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion. J Transl Med. 2013. doi: 10.1186/1479-5876-11-111.Google Scholar
  20. 20.
    Huang B, Zhou HL, Wang XD, Liu ZL. Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells. Cancer Cell Int. 2013. doi: 10.1186/1475-2867-13-8.Google Scholar
  21. 21.
    Zhang Y, Tian X, Ji H, Guan X, Xu W, Dong B, et al. Expression of SATB1 promotes the growth and metastasis of colorectal cancer. Plos One. 2014. doi: 10.1371/journal.pone.0100413.Google Scholar
  22. 22.
    Nodin B, Hedner C, Uhlén M, Jirström K. Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer. J Ovarian Res. 2012. doi: 10.1186/1757-2215-5-24.Google Scholar
  23. 23.
    Han S, Xia J, Qin X, Han S, Wu A. Phosphorylated SATB1 is associated with the progression and prognosis of glioma. Cell Death Dis. 2013. doi: 10.1038/cddis.2013.433.
  24. 24.
    Cheng C, Lu XM, Wang GB, Zhang L, Shu XJ, Zhu SK, et al. Expression of SATB1 and heparanase in gastric cancer and its relationship to clinico-pathologic features. APMIS. 2010;118:855–63.CrossRefPubMedGoogle Scholar
  25. 25.
    Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 2011;6:1179–89.CrossRefPubMedGoogle Scholar
  26. 26.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-△△Ct method. Methods. 2001;25:402–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Zhao XD, Ji WY, Zhang W, He LX, Yang J, Liang HJ, et al. Overexpression of SATBl in laryngeal squamous cell carcinoma. ORL. 2010;72:1–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Chu SH, Ma YB, Feng DF, Zhang H, Zhu ZA, Li ZQ, et al. Upregulation of SATB1 is associated with the development and progression of glioma. J Transl Med. 2012. doi: 10.1186/1479-5876-10-149.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Chen H, Takahara M, Oba J, Xie L, Chiba T, Takeuchi S, et al. Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma. J Dermatol Sci. 2011;64:39–44.CrossRefPubMedGoogle Scholar
  30. 30.
    Jafary H, Ahmadian S, Soleimani M. The enhanced apoptosis and antiproliferative response to combined treatment with valproate and nicotinamide in MCF-7 breast cancer cells. Tumor Biol. 2014;35:2701–10.CrossRefGoogle Scholar
  31. 31.
    Wang T, Cui H, Ma N, Jiang YH. Nicotinamide-mediated inhibition of SIRT1 deacetylase is associated with the viability of cancer cells exposed to antitumor agents and apoptosis. Oncol Lett. 2013;6:600–4.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Ogata S, Takeuchi M, Fujita H, Shibata K, Okumura K, Taguchi H. Apoptosis induced by nicotinamide-related compounds and quinolinic acid in HL-60 Cells. Biosci Biotechnol Biochem. 2000;64:327–32.CrossRefPubMedGoogle Scholar
  33. 33.
    Tu W, Luo M, Wang Z, et al. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver Int. 2012;32:1064–78.CrossRefPubMedGoogle Scholar
  34. 34.
    Han B, Luan L, Xu ZQ, Wu B. Expression and biological roles of SATB1 in human bladder cancer. Tumor Biol. 2013;34:2943–9.CrossRefGoogle Scholar
  35. 35.
    Chu SH, Zhou ZM, Feng DF, Ma YB. Inhibition of human glioma U251 cells growth in vitro and in vivo by hydroxyapatite nanoparticle-assisted delivery of short hairpin RNAs against SATB1. Mol Biol Rep. 2014;41:977–86.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Yan Zhang
    • 1
  • Haibo Wu
    • 1
  • Man Zhang
    • 1
  • Yali Jiang
    • 2
  • Weiwei Zhuo
    • 1
  • Yong Zhang
    • 1
  • Song Hua
    • 1
  1. 1.College of Veterinary MedicineNorthwest A&F UniversityYanglingChina
  2. 2.Northwest A&F University HospitalYanglingChina

Personalised recommendations